Logo

POAI

Predictive Oncology Inc.

POAI

Predictive Oncology Inc. • NASDAQ
$6.21 ▲ 5.25% (+0.31)
Market Cap $4.51 M
52w High $45.90
52w Low $4.76
Dividend Yield 0%
P/E -0.04
Volume 4.96K
Outstanding Shares 726.08K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.618K ▲ $3.275M ▲ $-77.652M ▼ -2.146M% ▼ $-107.25 ▼ $-77.614M ▼
Q2-2025 $2.682K ▼ $2.644M ▲ $-2.07M ▲ -77.198K% ▼ $-0.23 ▲ $-1.809M ▲
Q1-2025 $110.31K ▼ $2.352M ▼ $-2.443M ▼ -2.215K% ▼ $-0.341 ▲ $-2.121M ▼
Q4-2024 $611.585K ▲ $2.445M ▼ $-2.17M ▲ -354.749% ▲ $-0.398 ▲ $-1.55M ▲
Q3-2024 $345.686K $2.463M $-3.095M -895.232% $-0.612 $-2.273M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $181.667K ▼ $3.137M ▼ $80.565M ▲ $-77.428M ▼
Q2-2025 $506.078K ▼ $3.435M ▼ $5.089M ▼ $-1.653M ▼
Q1-2025 $3.088M ▲ $5.868M ▲ $6.014M ▲ $-145.796K ▲
Q4-2024 $734.673K ▼ $4.973M ▼ $5.175M ▼ $-202.61K ▼
Q3-2024 $3.079M $7.498M $5.531M $1.967M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-77.647M ▼ $-1.654M ▲ $0 $1.329M ▲ $-324.411K ▲ $-1.654M ▲
Q2-2025 $-1.979M ▲ $-3.324M ▼ $0 ▼ $726.906K ▼ $-2.582M ▼ $-3.324M ▼
Q1-2025 $-2.285M ▼ $-756.346K ▲ $625K ▲ $2.5M ▲ $2.353M ▲ $-756.35K ▲
Q4-2024 $-2.101M ▲ $-3.042M ▼ $32K ▲ $-195.776K ▼ $-2.344M ▼ $-3.042M ▼
Q3-2024 $-2.283M $-2.28M $0 $888.278K $-2.253M $-2.28M

Revenue by Products

Product Q1-2024Q2-2024Q3-2024Q4-2024
Pittsburgh
Pittsburgh
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Predictive Oncology’s income statement looks like that of an early-stage, still‑commercializing company. Revenue has effectively been non‑existent for several years, while operating expenses have continued, leading to steady losses each year. Those losses appear relatively small in absolute terms and have been kept fairly stable, suggesting some cost discipline. However, the core issue is that the technology platform has not yet translated into meaningful sales, so the business is still in the “investment and validation” phase rather than a proven commercial model. Reported earnings per share have been deeply negative, though reverse stock splits over time make those figures harder to interpret in a simple way.

Balance Sheet

Balance Sheet The balance sheet is very small and quite lean. Assets are modest and have largely consisted of cash and related items, with very little in the way of traditional physical assets. Debt has essentially been eliminated in recent years, which reduces financial risk, but equity is also thin because cumulative losses have eaten into the capital base. The repeated reverse stock splits over the company’s history strongly suggest that it has relied on issuing new shares to fund operations, leading to significant dilution for existing shareholders over time. Overall, financial resources look limited and tightly constrained, leaving little room for prolonged missteps without fresh funding.

Cash Flow

Cash Flow Cash flow mirrors the income statement: the company consistently spends more cash than it brings in from its operations. Operating cash burn has been steady and modest in size, but there is no offsetting inflow from revenue‑generating activities. Capital spending on equipment or facilities appears minimal, which means most cash outflow likely goes to staff, research, and overhead rather than to large physical investments. Free cash flow is therefore consistently negative, and the business is dependent on external capital raises or other financing to sustain its activities. Any delay in forming partnerships or generating service revenue directly increases the pressure on the cash position.

Competitive Edge

Competitive Edge Competitively, Predictive Oncology is positioned as a specialized player in AI‑driven oncology research. Its main strengths are a very large, proprietary biobank of human tumor samples, a patented active‑learning AI engine, and an integrated lab environment. Together, these can offer drug developers a more precise and efficient way to discover and de‑risk cancer therapies, which is a clear pain point in pharma. This combination of exclusive data plus specialized AI gives the company a meaningful niche and some barriers to entry. At the same time, the field of AI‑based drug discovery is crowded, with much larger and better‑funded competitors. The company’s unusual move into a “digital asset treasury” tied to a GPU network adds strategic complexity and introduces new types of risk that are outside traditional biotech norms. Its ability to convert its scientific advantages into stable, recurring commercial partnerships will largely determine its long‑term position.

Innovation and R&D

Innovation and R&D Innovation and R&D are where the company is strongest. The PEDAL platform, fueled by a large collection of patient‑derived tumors and guided by the CORE active‑learning engine, is designed to find promising drug‑tumor matches faster and with fewer experiments. The platform has shown high predictive accuracy in internal and collaborative work, and the company can extend this into drug repurposing, biomarker discovery, and clinical trial optimization. Its CLIA‑certified lab and 3D cell culture capabilities add credibility and depth to its scientific offering. Partnerships with respected academic and research groups underscore that the science is being taken seriously. However, these R&D strengths are not yet matched by a track record of material, predictable revenue. The newer digital‑asset/GPU strategy is experimental and should be watched closely to see whether it truly supports the core AI and R&D infrastructure or diverts focus and resources.

Summary

Predictive Oncology is a highly experimental, innovation‑driven company with promising technology but fragile financials. On the positive side, it owns differentiated assets in oncology: a large proprietary tumor biobank, a sophisticated AI discovery engine, and a certified lab platform that together form a credible, defensible niche in AI‑enabled cancer drug discovery and biomarker work. On the risk side, the business is still effectively pre‑revenue, loss‑making, and reliant on external funding, with a history of heavy dilution signaled by multiple reverse stock splits. Its balance sheet and cash flows leave little room for extended setbacks, and its recent foray into digital assets adds uncertainty to an already complex story. The key things to monitor are: the pace and quality of new partnerships, growth in paid discovery and biomarker projects, the company’s ability to manage cash without excessive dilution, and the outcome of any strategic alternatives it pursues, such as asset sales or mergers. Overall, this is a high‑uncertainty, high‑dependency situation where the scientific platform is far more mature than the commercial and financial profile.

NEWS

November 14, 2025 · 5:12 PM UTC

Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

Read more

October 14, 2025 · 8:00 AM UTC

Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

Read more

October 8, 2025 · 9:00 AM UTC

Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy

Read more

September 29, 2025 · 9:07 AM UTC

Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens

Read more

September 25, 2025 · 8:00 AM UTC

Predictive Oncology Announces 1-for-15 Reverse Stock Split

Read more